The Phase III trial AV001 aims to evaluate QUTENZA ® in post-surgical neuropathic pain (PSNP), a debilitating complication of surgery occurring after approximately 10 percent of all surgical ...

Investigators calculated annual OOP and total medication costs for five common neurological diseases. These included 186,144 ...